BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 25172783)

  • 1. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
    Xu HB; Shen ZL; Fu J; Xu LZ
    Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guggulsterone of Commiphora mukul resin reverses drug resistance in imatinib-resistant leukemic cells by inhibiting cyclooxygenase-2 and P-glycoprotein.
    Xu HB; Xu LZ; Mao XP; Fu J
    Phytomedicine; 2014 Jun; 21(7):1004-9. PubMed ID: 24680616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines.
    Xu HB; Li L; Liu GQ
    Chemotherapy; 2011; 57(1):62-70. PubMed ID: 21282948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversion of P-glycoprotein-mediated multidrug resistance by guggulsterone in multidrug-resistant human cancer cell lines.
    Xu HB; Xu LZ; Li L; Fu J; Mao XP
    Eur J Pharmacol; 2012 Nov; 694(1-3):39-44. PubMed ID: 22960326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft.
    Azab SS; Salama SA; Hassan MH; Khalifa AE; El-Demerdash E; Fouad H; Al-Hendy A; Abdel-Naim AB
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):893-902. PubMed ID: 18253735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J; Wang FP; Wei H; Liu G
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression.
    De U; Chun P; Choi WS; Lee BM; Kim ND; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2014 Jan; 44(1):167-76. PubMed ID: 24190517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
    Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
    Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
    Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guggulsterone sensitized drug-resistant human hepatocarcinoma cells to doxorubicin through a Cox-2/P-gp dependent pathway.
    Xu HB; Fu J; Huang F; Yu J
    Eur J Pharmacol; 2017 May; 803():57-64. PubMed ID: 28342979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae.
    Huang M; Jin J; Sun H; Liu GT
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1015-26. PubMed ID: 18270702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
    Chen LM; Liang YJ; Zhang X; Su XD; Dai CL; Wang FP; Yan YY; Tao LY; Fu LW
    Anticancer Res; 2009 Nov; 29(11):4597-604. PubMed ID: 20032409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
    Ren Y; Wang Y; Zhang Y; Wei D
    Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.